EMG
ITCI

Ellington Management Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ellington Management Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-17,000
Closed -$246K – 1056
2017
Q4 		$246K Buy
17,000
+3,600
+27% +$55.6K 0.04% 422
2017
Q3 		$211K Buy
+13,400
New +$197K 0.04% 512
2017
Q2 		– Sell
-15,000
Closed -$244K – 942
2017
Q1 		$244K Sell
15,000
-3,200
-18% -$46.3K 0.01% 517
2016
Q4 		$275K Buy
+18,200
New +$257K 0.04% 355

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ellington Management Group's ITCI Position: Q1 2018 in Review

Ellington Management Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2018, closing a stake of 17,000 shares — an estimated $246K sold.

Ellington Management Group first reported a position in ITCI in Q4 2016 and held it in 4 quarters. The position peaked at $275K in Q4 2016. 131 funds tracked by Wall St. Rank hold ITCI as of Q1 2018.

  • Ellington Management Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2018 after selling out during the quarter.
  • Ellington Management Group sold 17,000 Intra-Cellular Therapies Inc. shares in Q1 2018, an estimated $246K.
  • Ellington Management Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 4 quarters.
  • Ellington Management Group's Intra-Cellular Therapies Inc. position peaked at $275K in Q4 2016.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2018.

Based on Ellington Management Group's 13F filing for Q1 2018, filed 15 May 2018.